BioSpace News Archive

Infinity Pharmaceuticals, Inc. announced that Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals, will provide a corporate overview at the 38th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 9:00 am Pacific Time at the Westin St. Francis Hotel in San Francisco, California.

Tmunity Therapeutics, Inc. announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:30 pm Pacific Time at the Westin St. Francis Hotel in San Francisco.

F-star Therapeutics announces the appointments of Dr. Edward Benz and Mr. Geoff Race to its Board of Directors, further strengthening the depth and breadth of its clinical and industry expertise.

Nephros, Inc. announced that it has formally launched PluraPathTM, the only commercially available portable water pathogen detection system designed to provide actionable data for infection control teams on up to 15 different pathogens from a single water sample, in approximately one hour.

Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million

Encompass Health Corp. announced it will report results for its fourth quarter ended Dec. 31, 2019, after the market closes on Feb. 6, 2020. The Company will host an investor conference call at 9 a.m. ET on Feb. 7, 2020, to discuss its results..

Infinity Pharmaceuticals, Inc. announced a $20 million non-dilutive asset-backed financing with BVF Partners L.P., Infinity’s largest shareholder.

Research teams will use stem cell and gene editing technologies to advance NK cell-based therapies for cancer

This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients

eFFECTOR Therapeutics, Inc. and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways.